Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Unsuccessful drug against anxiety opens a novel gateway for the treatment of cancer

05.09.2008
According a new study, unsatisfying drug for anxiety reveals scientists a promising novel anti-cancer drug target.

Cancer cells have multiple ways to avoid apoptosis, programmed cell death the means by which organisms deal with defective cells. One defense is to produce quantities of phosphatic acid, a phospholipid constituent of cellular membranes.

Unlike other phospholipids, phosphatidic acid also acts as a signaling molecule for cells promoting cellular growth and preventing apoptosis. Finnish and Danish researchers have now shown that phosphatidic acid may well be a target molecule for novel anti-cancer drugs.

Siramesine is a drug molecule developed and synthesized by Lundbeck A/S for the treatment of anxiety. Its development was discontinued due to unsatisfying efficacy in clinical trials in 2002. Later professor Marja Jäättelä and co-workers at the Danish cancer institute discovered that siramesine effectively inhibits the growth of both cultured cancer cells as well as solid tumors in mice. Siramesine is known to bind sigma-receptors, which physiological role remains unknown, on the cellular surface and this interaction was also believed to underlie its anti-tumor actions.

Researchers at the University of Helsinki, Finland, lead by Professor Paavo Kinnunen, studied the interaction of this drug with different phospholipids using biophysical methods and different model cellular membranes. In addition a computer simulation was performed as collaboration with MEMPHYS, Odense, Denmark, to further their understanding of this interaction.

“The key finding of our study was that siramesine avidly and specifically binds to phosphatidic acid”, says MD Mikko Parry from Helsinki Biophysics & Biomembrane group at the Institute of Biomedicine, University of Helsinki.

“Importantly, this is the first time it’s shown that a lipid second messenger can act as a drug target: it is a totally new mechanism of action and constitutes a novel paradigm for developing new, more effective anti-cancer drugs.”

Paivi Lehtinen | alfa
Further information:
http://www.helsinki.fi

More articles from Studies and Analyses:

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>